Carregant...

Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer

Pancreatic cancer is highly malignant with limited therapy and a poor prognosis. TRAIL-activating therapy has been promising, however, clinical trials have shown resistance and limited responses of pancreatic cancers. We investigated the effects of calmodulin(CaM) antagonists, trifluoperazine(TFP) a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Yuan, Kaiyu, Yong, Sun, Xu, Fei, Zhou, Tong, McDonald, Jay M, Chen, Yabing
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2015
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4694833/
https://ncbi.nlm.nih.gov/pubmed/26320171
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!